Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIndivior Regulatory News (INDV)

Share Price Information for Indivior (INDV)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,318.00
Bid: 1,315.00
Ask: 1,319.00
Change: 43.00 (3.37%)
Spread: 4.00 (0.304%)
Open: 1,289.00
High: 1,318.00
Low: 1,267.00
Prev. Close: 1,275.00
INDV Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Civil Complaint Filed by State Attorneys General

23 Sep 2016 07:00

RNS Number : 6244K
Indivior PLC
23 September 2016
 

Indivior PLC

 

Indivior Notified of Civil Complaint Filed by State Attorneys General

 

Slough, UK, 23 September 2016 - Further to the update on the FTC investigation and class action litigation previously disclosed on 29 July 2016, the Company was notified yesterday that thirty-five U.S. states and the District of Columbia filed a civil complaint alleging violations of state and federal antitrust and consumer protection laws. The Company intends to continue to vigorously defend its position.

 

 

Forward-Looking Statements

This press release contains forward-looking statements. We may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations.

 

Various factors may cause differences between Indivior's expectations and actual results, including: factors affecting sales of Indivior products and any future products; the outcome of research and development activities; decisions by regulatory authorities regarding the Indivior Group's drug applications; the speed with which regulatory authorizations, pricing approvals and product launches may be achieved; the outcome of post-approval clinical trials; competitive developments; difficulties or delays in manufacturing; the impact of existing and future legislation and regulatory provisions on product exclusivity; trends toward managed care and healthcare cost containment; legislation or regulatory action affecting pharmaceutical product pricing, reimbursement or access; claims and concerns that may arise regarding the safety or efficacy of the Indivior Group's products and product candidates; risks related to legal proceedings; the Indivior Group's ability to protect its patents and other intellectual property; the outcome of patent litigation relating to ongoing ANDA lawsuits; changes in governmental laws and regulations; issues related to the outsourcing of certain operational and staff functions to third parties; uncertainties related to general economic, political, business, industry, regulatory and market conditions; and the impact of acquisitions, divestitures, restructurings, internal reorganizations, product recalls and withdrawals and other unusual items.

 

Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

 

About Indivior

 

Indivior is a global specialty pharmaceutical company with a 20-year legacy of leadership in patient advocacy, health policy and evidence-based best practice models that have revolutionized modern addiction treatment. The name is the fusion of the words individual and endeavor, and the tagline "Focus on you" makes the company's commitment clear. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease. Building on its robust, global opioid dependence portfolio, Indivior has a strong pipeline of product candidates designed to both expand on its heritage in this category and address other chronic diseases of addiction - including opiate overdose, alcohol use disorders, and cocaine intoxication. It also is pursuing novel product candidates in related mental health disorders such as schizophrenia. Headquartered in the United States in Richmond, VA, Indivior employs more than 900 individuals globally and its portfolio is available in over 40 countries worldwide. Visit www.Indivior.com to learn more.

 

 

 

Media Inquiries

Email: IndiviorMediaContacts@indivior.com

Phone: +1 804-594-0836

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCLJMTTMBTTMTF
Date   Source Headline
2nd Mar 202212:22 pmRNSDirector/PDMR Shareholding
18th Feb 202212:10 pmRNSDirector/PDMR Shareholding
16th Feb 20227:00 amRNSFinal Results
1st Feb 202211:41 amRNSTotal Voting Rights
1st Feb 20229:23 amRNSNotice of Results
28th Jan 20227:00 amRNSBuprenorphine-Fentanyl Interaction Study Results
4th Jan 202210:53 amRNSTotal Voting Rights
29th Dec 20211:00 pmRNSTransaction in Own Shares
24th Dec 20217:00 amRNSTransaction in Own Shares
23rd Dec 20217:00 amRNSTransaction in Own Shares
22nd Dec 20217:00 amRNSTransaction in Own Shares
21st Dec 20217:00 amRNSTransaction in Own Shares
20th Dec 20217:00 amRNSTransaction in Own Shares
17th Dec 20217:00 amRNSTransaction in Own Shares
16th Dec 20217:00 amRNSTransaction in Own Shares
15th Dec 20213:13 pmRNSBlock Listing Application
15th Dec 20217:00 amRNSTransaction in Own Shares
14th Dec 20217:00 amRNSTransaction in Own Shares
13th Dec 20217:00 amRNSTransaction in Own Shares
10th Dec 20217:00 amRNSTransaction in Own Shares
9th Dec 20217:00 amRNSTransaction in Own Shares
8th Dec 20217:00 amRNSTransaction in Own Shares
7th Dec 20217:00 amRNSTransaction in Own Shares
6th Dec 20217:00 amRNSTransaction in Own Shares
3rd Dec 20217:00 amRNSTransaction in Own Shares
2nd Dec 20217:00 amRNSTransaction in Own Shares
1st Dec 202111:52 amRNSTotal Voting Rights
1st Dec 20217:00 amRNSTransaction in Own Shares
30th Nov 20214:05 pmRNSDirector/PDMR Shareholding
30th Nov 20217:00 amRNSTransaction in Own Shares
29th Nov 20217:00 amRNSTransaction in Own Shares
26th Nov 20217:00 amRNSTransaction in Own Shares
25th Nov 20217:00 amRNSTransaction in Own Shares
24th Nov 20217:00 amRNSTransaction in Own Shares
23rd Nov 20217:00 amRNSTransaction in Own Shares
22nd Nov 20217:00 amRNSTransaction in Own Shares
19th Nov 20217:00 amRNSTransaction in Own Shares
18th Nov 20214:00 pmRNSDirector Declaration
18th Nov 20217:00 amRNSTransaction in Own Shares
17th Nov 20217:00 amRNSTransaction in Own Shares
16th Nov 20217:00 amRNSTransaction in Own Shares
15th Nov 202110:00 amRNSHolding(s) in Company
15th Nov 20217:00 amRNSTransaction in Own Shares
12th Nov 20217:00 amRNSTransaction in Own Shares
11th Nov 20217:00 amRNSTransaction in Own Shares
10th Nov 20219:30 amRNSBlock listing Interim Review
10th Nov 20217:00 amRNSResult of placing of existing shares in Indivior
10th Nov 20217:00 amRNSTransaction in Own Shares
9th Nov 20214:37 pmRNSProposed placing of existing shares in Indivior
9th Nov 20217:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.